To each his own: a personalized vaccine for metastatic melanoma.
作者信息
Chiocchetti Annalisa, Cappellano Giuseppe, Dianzani Umberto
机构信息
Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases, University of Piemonte Orientale, Novara, Italy.
Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
出版信息
Gland Surg. 2019 Aug;8(4):329-333. doi: 10.21037/gs.2017.11.03.
Abstract
摘要
相似文献
1
To each his own: a personalized vaccine for metastatic melanoma.因人而异：转移性黑色素瘤的个性化疫苗
Gland Surg. 2019 Aug;8(4):329-333. doi: 10.21037/gs.2017.11.03.
2
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.KEYNOTE - D36：晚期黑色素瘤中使用新抗原疫苗EVX - 01和帕博利珠单抗的个性化免疫疗法。
Future Oncol. 2022 Oct;18(31):3473-3480. doi: 10.2217/fon-2022-0694. Epub 2022 Sep 1.
3
A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma.单臂 I 期剂量递增试验设计：用 IKKβ 成熟的负载 RNA 的树突状细胞进行个体化免疫接种治疗转移性葡萄膜黑色素瘤。
Front Immunol. 2022 Feb 4;13:785231. doi: 10.3389/fimmu.2022.785231. eCollection 2022.
4
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.个体化肽类新抗原疫苗（EVX-01）治疗转移性黑色素瘤的递增剂量研究。
J Immunother Cancer. 2024 May 23;12(5):e008817. doi: 10.1136/jitc-2024-008817.
5
Establishment of stable cell lines for personalized melanoma cell vaccine.建立稳定的细胞系用于个体化黑素瘤细胞疫苗。
Melanoma Res. 2010 Aug;20(4):280-92. doi: 10.1097/CMR.0b013e3283390696.
6
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.采用包含新型佐剂 CAF®09b 的基于肽的新生抗原疫苗（EVX-01）进行个体化治疗，用于转移性黑色素瘤患者。
Oncoimmunology. 2022 Jan 10;11(1):2023255. doi: 10.1080/2162402X.2021.2023255. eCollection 2022.
7
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.自体肿瘤裂解物颗粒负载树突细胞疫苗接种联合系统治疗在复发性和转移性黑色素瘤患者中的安全性和有效性。
Melanoma Res. 2021 Aug 1;31(4):378-388. doi: 10.1097/CMR.0000000000000758.
8
Development of Personalized Strategies for Precisely Battling Malignant Melanoma.制定精确打击恶性黑素瘤的个体化策略。
Int J Mol Sci. 2024 May 4;25(9):5023. doi: 10.3390/ijms25095023.
9
BRAF Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist.BRAF 转移性黑色素瘤之旅：患者和肿瘤医生的视角。
Adv Ther. 2024 Jul;41(7):2576-2585. doi: 10.1007/s12325-024-02883-0. Epub 2024 May 28.
10
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.转移性黑色素瘤的个体化靶向治疗及无创性肿瘤监测的进展
Front Oncol. 2013 Mar 19;3:54. doi: 10.3389/fonc.2013.00054. eCollection 2013.
引用本文的文献
1
Polypeptides-Based Nanocarriers in Tumor Therapy.基于多肽的纳米载体在肿瘤治疗中的应用
Pharmaceutics. 2024 Sep 10;16(9):1192. doi: 10.3390/pharmaceutics16091192.
2
Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics.用于肿瘤免疫治疗的纳米药物递送系统：下一代疗法。
Front Oncol. 2022 May 19;12:864301. doi: 10.3389/fonc.2022.864301. eCollection 2022.
本文引用的文献
1
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.个体化 RNA 突变疫苗可动员针对癌症的多特异性治疗性免疫。
Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.
2
An immunogenic personal neoantigen vaccine for patients with melanoma.一种用于黑色素瘤患者的免疫原性个人新抗原疫苗。
Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5.
3
The use of immunotherapy in the treatment of melanoma.免疫疗法在黑色素瘤治疗中的应用。
J Hematol Oncol. 2017 Apr 24;10(1):88. doi: 10.1186/s13045-017-0458-3.
4
Elements of cancer immunity and the cancer-immune set point.癌症免疫的要素和癌症免疫基准。
Nature. 2017 Jan 18;541(7637):321-330. doi: 10.1038/nature21349.
5
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
6
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.黑色素瘤GVAX的安全性及免疫相关性，一种在辅助治疗中应用的分泌GM-CSF的同种异体黑色素瘤细胞疫苗。
J Transl Med. 2015 Jul 5;13:214. doi: 10.1186/s12967-015-0572-3.
7
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.CTLA-4与PD-1通路阻断：临床中的联合应用
Front Oncol. 2015 Jan 15;4:385. doi: 10.3389/fonc.2014.00385. eCollection 2014.
8
Tumor cell lysates as immunogenic sources for cancer vaccine design.肿瘤细胞裂解物作为癌症疫苗设计的免疫原性来源。
Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996.
9
B7h triggering inhibits the migration of tumor cell lines.B7h 触发抑制肿瘤细胞系的迁移。
J Immunol. 2014 May 15;192(10):4921-31. doi: 10.4049/jimmunol.1300587. Epub 2014 Apr 11.
10
Developing mRNA-vaccine technologies.mRNA 疫苗技术的发展。
RNA Biol. 2012 Nov;9(11):1319-30. doi: 10.4161/rna.22269. Epub 2012 Oct 12.
Zotero 插件